Gender differences in p-glycoprotein: Drug toxicity and response [3]

Journal of Clinical Oncology

Volumn 23, Issue 26, 2005, Pages 6439-6440

  Davis, Mellar ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; VINCRISTINE; ANTINEOPLASTIC AGENT; GLYCOPROTEIN;

ADVERSE DRUG REACTION; BONE MARROW SUPPRESSION; CANCER SURVIVAL; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; HUMAN; LETTER; NAUSEA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SMALL CELL CARCINOMA; STOMATITIS; VOMITING; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; DRUG TOXICITY; FEMALE; FOLLOW UP; LAW; LUNG TUMOR; MALE; METABOLISM; MORTALITY; NOTE; PATHOLOGY; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CLINICAL TRIALS; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MALE; RISK ASSESSMENT; SEX FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 27244455418     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.9232     Document Type: Letter

References (15)

1. Singh S, Parulekar W, Murray N, et al: Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 23:850-856, 2005
2. Baumhakel M, Kasel D, Roa-Schymanski RA, et al: Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human microsomes. Int J Clin Pharmacol Ther 39:517-528, 2001
3. Toffoli G, Corona G, Basso B, Boiocchi M: Pharmacokinetic optimization of treatment with oral etoposide. Clin Pharmacokint 43:441-66, 2004
4. Stephens RH, O'Neill CA, Bennett J, et al: Resolution of P-glycoprotein and non p-glycoprotein effects on drug permeability using intestinal tissues from MDR IA (-/-) mice. Br J Pharmacol 135:2038-2046, 2002
5. Benet LZ, Cummins CL: The drug efflux: Metabolism alliance-Biochemical aspects. Adv Drug Deliv Rev 50:S3-S11, 2001
6. Benet LZ, Cummins CL, Wu CY: Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277:3-9, 2004
7. Marzolini C, Paus E, Buclin T, et al: Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33, 2004
8. Kim RB: Transporters and xenobiotic disposition. Toxicology 181-182:291-297, 2002
9. van Asperen J, Schinkel AH, Beijnen JH, et al: Altered pharmacokinetics of vinblastine in MDR IA P-glycoprotein deficient mice. J Natl Cancer Inst 88:994-999, 1996
10. van Asperen J, van Tellingen O, Tijssen F, et al: Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr Ia P-glycoprotein. Br J Cancer 79:108-113, 1999
11. van Asperen J, van Tellingen O, Schinkel AH, et al: Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr Ia P-glycoprotein. J Pharmacol Exp Ther 289:329-333, 1999
12. Schuetz EG, Furuya KN, Scheutz JD: Interindividual variation in expression of P-Glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275:1011-1018, 1995
13. Cummins CL, Wu C, Benet LZ: Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 72:474-489, 2002
14. Yokogawa K, Takahashi M, Tamai I, et al: P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdr Ia knockout mice Pharm Res 16:1213-1218, 1999
15. Chiou WL, Chung SM, Wu, Ta C: Potential role of P-Glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 17:903-905, 2000